Pfizer (NYSE:PFE) Trading 1.4% Higher - Here's Why

Key Points

• Pfizer shares rose 1.4% to about $26.18 on heavier-than-average trading after the company reported second-quarter adjusted EPS of $0.77 and revenue of $15.03 billion, both above analyst expectations.
• Management raised the low end of its 2026 revenue outlook and increased its cost-reduction target to $2.5 billion, supported by stronger demand for non-COVID products such as Eliquis.
• Despite the improved results, analysts remain cautious, with a consensus “Hold” rating and a $28.50 price target; declining COVID sales, obesity-program challenges and patent expirations remain key risks.

Pfizer Inc. (NYSE:PFE - Get Free Report) shares traded up 1.4% on Thursday . The company traded as high as $26.20 and last traded at $26.1840. Approximately 49,975,867 shares changed hands during mid-day trading, an increase of 18% from the average session volume of 42,435,234 shares. The stock had previously closed at $25.81.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 earnings beat expectations: Pfizer reported adjusted EPS of $0.77 versus the $0.68 consensus estimate, while revenue of $15.03 billion exceeded expectations of $14.40 billion. Strong demand for Eliquis and other non-COVID products helped offset weaker COVID-related sales. Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: Raised outlook and deeper cost savings: Management increased the low end of its 2026 revenue guidance and raised its cost-reduction target to $2.5 billion. Investors viewed the savings program and continued non-COVID growth as evidence that Pfizer’s recovery is progressing despite the post-pandemic revenue reset. Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
• Positive Sentiment: Pipeline updates add longer-term support: Pfizer and BioNTech reported an update on a next-generation pediatric COVID booster study, while Pfizer completed an early Phase 1 study of PF-07328948. The company also reported positive Phase 3 LITFULO data in vitiligo, providing additional potential growth catalysts. Pfizer and BioNTech Lock In Next-Gen Pediatric COVID Booster Edge
• Positive Sentiment: Income appeal remains a factor: Recent coverage highlights Pfizer’s high dividend yield and its dividend increase, which may attract income-oriented investors while the company rebuilds its product portfolio. After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?
• Neutral Sentiment: Analyst views remain mixed: RBC Capital maintained a Hold rating, indicating that improved operating performance has not fully removed concerns about Pfizer’s longer-term growth profile. RBC Capital Remains a Hold on Pfizer
• Negative Sentiment: COVID and obesity setbacks remain risks: Revenue from Pfizer’s COVID pill reportedly fell sharply, while challenges surrounding its obesity program and upcoming patent expirations could limit growth. Investors will need evidence that newer products and pipeline candidates can replace declining legacy revenue. Pfizer Covid Pill Revenue Plunges 95%. The Stock Is Rising Anyway.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on PFE. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Morgan Stanley upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company an "equal weight" rating in a research note on Friday, April 10th. HSBC lowered Pfizer from a "buy" rating to a "hold" rating and dropped their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Cantor Fitzgerald restated a "neutral" rating and set a $27.00 price target on shares of Pfizer in a research note on Monday, July 6th. Finally, JPMorgan Chase & Co. cut their price objective on Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $28.50.

Pfizer Trading Up 1.4%

The firm has a market capitalization of $149.23 billion, a P/E ratio of 34.45 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The business has a 50-day moving average price of $25.01 and a 200-day moving average price of $26.16.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.38%. The company had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the prior year, the company posted $0.78 EPS. The business's revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer's dividend payout ratio (DPR) is currently 226.32%.

Institutional Investors Weigh In On Pfizer

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares during the period. KBC Group NV boosted its position in shares of Pfizer by 8.3% in the fourth quarter. KBC Group NV now owns 9,193,713 shares of the biopharmaceutical company's stock valued at $228,924,000 after acquiring an additional 706,426 shares during the period. North Dakota State Investment Board acquired a new position in shares of Pfizer in the fourth quarter valued at about $5,348,000. PFA Pension Forsikringsaktieselskab acquired a new stake in Pfizer in the 4th quarter worth about $76,833,000. Finally, John G Ullman & Associates Inc. boosted its holdings in Pfizer by 35.0% in the 4th quarter. John G Ullman & Associates Inc. now owns 206,065 shares of the biopharmaceutical company's stock valued at $5,131,000 after purchasing an additional 53,467 shares during the period. 68.36% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source